Načítá se...
Global access of rifabutin for the treatment of tuberculosis – why should we prioritize this?
INTRODUCTION: Rifabutin, a rifamycin of equivalent potency to rifampicin, has several advantages in its pharmacokinetic and toxicity profile, particularly in HIV co‐infected patients on combined antiretroviral therapy (cART). In this commentary, we evaluate evidence supporting increased global use o...
Uloženo v:
| Vydáno v: | J Int AIDS Soc |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley and Sons Inc.
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6637439/ https://ncbi.nlm.nih.gov/pubmed/31318176 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jia2.25333 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|